Decreased Aerobic Capacity in ANO5-Muscular Dystrophy.

Area of Science:

• Muscle physiology and genetics
• Neuromuscular disorders
• Mitochondrial function and exercise capacity

Background:

• Anoctaminopathies are genetic muscle diseases linked to recessive ANO5 gene mutations.
• Previous research has not systematically evaluated the impact of anoctaminopathy on oxidative capacity.
• Understanding these effects is crucial for managing the disease and patient care.

Purpose of the Study:

• To precisely characterize the oxidative capacity in a well-defined group of patients with anoctaminopathy.
• To correlate genetic findings with clinical presentation and functional limitations.
• To establish a baseline for future therapeutic interventions.

Main Methods:

• Genetic sequencing of the ANO5 gene in 111 Finnish patients with suspected limb-girdle muscular dystrophy type 2 (LGMD2).
• Clinical evaluation including electromyography, muscle MRI, and muscle biopsy.
• Spiroergometry to assess oxidative capacity, compared with healthy controls.

Main Results:

• 14 patients from 11 families were characterized, predominantly with the Finnish founder variant (c.2272C>T).
• Muscle MRI showed progressive fatty degeneration in specific lower limb muscles.
• Spiroergometry revealed significantly impaired oxidative capacity and increased ventilation in patients.

Conclusions:

• Anoctaminopathy is characterized by slow progression, consistent with prior reports.
• The study demonstrates a significant impairment of aerobic exercise capacity in patients with ANO5-related muscle disease.
• These findings underscore the importance of assessing cardiovascular and respiratory function in anoctaminopathy patients.